Although most cases of tuberculosis (TB) can be cured with antibiotics, relapse is common if patients do not continue chemotherapy for at least 6 months. Thus, improved therapeutic strategies are urgently needed. We previously found that the combined DNA vaccine encoding the Mycobacterium tuberculosis proteins Ag85B, MPT-64 and MPT-83 protected mice from TB following H37Rv challenge and considered whether this combined DNA vaccine has a therapeutic effect. In the present work, we demonstrate that boosting the efficiency of the immune system with the combined DNA vaccine may be a valuable adjunct to shorten the duration of antibacterial chemotherapy. Mice treated with the combined DNA vaccine along with isoniazid and pyrazinamide showed significantly higher interferon-g responses to a mixture of the three specific antigens (Po0.001), which were accompanied by a significant reduction in colony-forming unit in H37Rv-infected animals 3-5 months after treatment (Po0.001). These results suggest that the combined DNA vaccine along with conventional TB chemotherapy has strong potential for TB immunotherapy and may provide new alternatives to control the disease.
Introduction
One-third of the world's population is currently infected with the tuberculosis (TB) bacillus Mycobacterium tuberculosis, and three million people die of TB each year. These staggering numbers make TB one of the leading infectious disease killers. [1] [2] [3] [4] The situation is worsened by the increasing incidence of both multidrug-resistant strains and combined infection with TB and AIDS. The chemotherapeutic regimens available for treatment of TB are far from ideal, requiring the ingestion of multiple anti-TB drugs over prolonged periods. The side effects of current drug regimens, combined with the protracted duration of treatment, frequently result in poor patient compliance, treatment failures and associated emergence of drug resistance with major financial implications. 3 Therefore, development of more effective, shorter treatments for TB is now an urgent requirement. Most infected people never develop active disease. However, in approximately 10% of infected subjects, the reactivation of latent infection results in active TB. 5 Therefore, immune response adequately controls infection in most people but apparently is not generally effective in destroying the intracellular bacteria. 6 In these circumstances, to boost the efficiency of the immune system in infected patients, immunotherapy could be a valuable adjunct to antibacterial chemotherapy.
DNA vaccination has been pursued for TB therapy because it establishes cellular immune responses, including cytotoxic T-lymphocyte and Th1 responses. Th1 immune responses are thought to drive the induction of cellular immunity, whereas Th2 immune responses preferentially drive humoral immunity. The Th1-type cytokine interferon (IFN)-g is essential for the control of experimental TB in mice, and was the first human immunologic factor to be identified as essential for resistance against mycobacterial infection.
7, 8 The DNA vaccine can switch from a relatively inefficient Th2 immune response to a Th1 response, thereby causing bacterial stasis or a bactericidal response. Thus, this DNA vaccine, initially designed to prevent infection by M. tuberculosis, can also have pronounced therapeutic action in mice. 9, 10 Several additional studies have shown promising results for DNA vaccination against TB. Prophylactic DNA vaccines expressing various M. tuberculosis antigens, including Ag85A, Ag85B, MTP-64, ESAT-6, 65-kDa heat-shock protein and PstS-3, were found to be effective at limiting the growth of M. tuberculosis in heavily infected mice. [11] [12] [13] [14] After the completion of chemotherapy in mice infected with M. tuberculosis intravenously, vaccination with plasmid DNA expressing 65-kDa heat-shock protein was effective in preventing reactivation.
could effectively prevent reactivation of aerogenically transmitted M. tuberculosis. Immunotherapy using a plasmid DNA encoding mycobacterial 85A antigen or interleukin (IL)-12N220L DNA vaccine combined with conventional chemotherapy was highly effective in preventing TB reactivation in mice. 12 A double-gene DNA vaccine composed of Ag85A and PstS-3 genes could reduce bacterial growth better than the single-gene DNA vaccines during the period of chemotherapy after a secondary reinfection. 13 Therapeutic effects of Ag85B and MPT64 DNA vaccines indicated that Ag85B DNA vaccination had immunotherapeutic effects on TB in mice, whereas MPT64 DNA did not. 15 More importantly, it seems that the timing of DNA vaccination may be a major factor in determining the efficacy of the vaccine in a latent model because DNA vaccination against TB may minimize granuloma formation and/or necrosis induction when simultaneously combined with chemotherapy; DNA vaccine-induced Th1 and cytotoxic T-lymphocyte responses may act together with chemotherapy to eliminate M. tuberculosis. Therefore, we investigated whether combined DNA vaccine immunotherapy used with chemotherapy is more effective at controlling M. tuberculosis infection in mice. Our results show that immunotherapy using the combined DNA vaccine with Ag85B, MPT-83 and MPT-64 antigens in combination with chemotherapy could be effective in the prevention of TB reactivation and may be a promising strategy for controlling M. tuberculosis infection.
Results
The combined DNA vaccine along with isoniazid and pyrazinamide induces stronger antigen-specific type 1 cellular immune responses
To investigate the therapeutic effect of DNA vaccines (Figure 1a ) on the reactivation of primary infection in a chronically infected state, mice were intravenously infected with live M. tuberculosis H37Rv (5 Â 10 5 organisms) (Figure 1b) . At 32 weeks post-infection, we stimulated splenocytes of isoniazid (INH)+pyrazinamide (PZA)-treated mice with a mixture of the antigens and/ or purified protein derivative (PPD) and determined the levels of IFN-g production by ELISA (Figure 2 ). Interestingly, mice immunized with empty vector DNA during the course of chemotherapy showed a higher level of IFN-g production in response to the mixture of the three proteins or PPD than mice given chemotherapy alone, suggesting that the CpG motifs in the DNA vector could work as an inducer of the Th1 immune response, as reported. 16 As expected, mice treated with the combined DNA vaccine along with INH+PZA showed a significantly higher level of IFN-g production in response to the mixture of the three proteins or PPD compared with mice treated with only INH+PZA (Po0.001 and Po0.01, respectively) ( Figure 2a ). We found no significant difference in IL-4 production in response to the mixture of the three antigens or PPD in any group (Figure 2b) .
The higher secretion of IFN-g measured by ELISA paralleled a substantial increase in the number of antigen-specific cells in the spleen, as measured by in vitro ELISPOT ( Figure 3 ). As expected, mice treated with the combined DNA vaccine plus INH+PZA had a significantly higher number of IFN-g-producing cells (about 176 per 10 5 cells) specific for the mixture of the three antigens and PPD than those treated with only INH+PZA or with INH+PZA plus empty vector (about 36 per 10 5 cells) (Po0.001 and Po0.01, respectively). Among splenocytes from mice given combined treatment with the vaccine and drugs, the frequency of T cells producing IFN-g in response to the antigen mixture was higher than the frequency of those responding to PPD. This was not observed among splenocytes from mice given the drugs and empty plasmid treatment. This was consistent with a Th1 response to the DNA vaccine antigens (Figure 3 ). The present findings strengthen the case for evaluating immunotherapy as a complement to chemotherapy for the treatment of TB. We determined bacterial counts in the organs of mice at 32 or 40 weeks post-infection (12 or 20 weeks after the completion of a 12-week chemotherapy; Table 1 ). Mice treated with only INH+PZA showed the highest residual infection rates in both lung and spleen (80 and 100%, respectively, at 32 weeks post-infection, and 60 and 80%, respectively, at 40 weeks post-infection), as mentioned above. Interestingly, viable M. tuberculosis was recovered from the lungs and spleens of only three (60%) of five mice that were treated with empty plasmid DNA, suggesting again that the CpG motifs in the vector Table 1 ). A significant reduction in the reactivation of M. tuberculosis was observed in the lungs of mice immunized with the combined DNA vaccine along with INH+PZA (Po0.01). Interestingly, the rates of reactivation in both lung and spleen appeared to correlate with IFN-g production specific to the antigens, consistent with the fact that antigen-mediated Th1 immunity has a prominent role in protection against M. tuberculosis. These results indicate that the combined DNA vaccine along with INH+PZA chemotherapy can be used as a genetic adjuvant to prevent the reactivation of M. tuberculosis. Thirty-two weeks after beginning treatment, the combined DNA vaccine along with INH+PZA enabled a significant reduction in colony-forming units in H37Rv-infected animals compared with that of control mice injected with only INH+PZA (Po0.001; Table 2 ). These findings will have particular importance if the application of combined DNA in conjunction with conventional chemotherapeutic antibacterial drugs results in a faster and more certain cure of the disease.
Histopathological changes in lung tissues treated with the combined DNA vaccine plus INH+PZA were observed at week 8 post-infection. Majority of air spaces in the lung were filled with epithelioid macrophages (Figure 5a ). At this point in time, bacterial numbers in the lungs had reached 8.22±0.76 ( Â 10 5 ) colony-forming units. At week 20 post-infection, most of the infiltrated cells were found to have disappeared, resulting in a clear air space (Figure 5b) . Also, no signs of lymphocyte infiltration were observed at 32 weeks post-infection (Figure 5c ). These results indicate that the combined DNA vaccine plus INH+PZA are effective in preventing progressive pulmonary pathology after infection.
The combined DNA vaccine along with INH+PZA induces higher levels of IL-12 and nitric oxide Macrophage response against M. tuberculosis is of primary importance in host defense. Moreover, macrophages serve as antigen-presenting cells and are also potent effectors of inflammation because of their capacity to secrete a wide array of chemical mediators. 17 The characterization of these mediators is extremely important to better understand the role of macrophages in the initiation and modulation of the immune response in TB under treatment with combined DNA vaccine and drugs. Splenic macrophages from mice treated with the combined DNA vaccine along with INH+PZA produced significantly higher levels of IL-12 (Po0.001) at 32 and 40 weeks post-infection than those from mice treated with only INH+PZA or INH+PZA plus empty vector. These splenic macrophages also produced nitric oxide (NO) in significantly higher quantities (Po0.01) at the same time points (Table 3 ), suggesting that the combined DNA vaccine could enhance both innate (natural killer cell) and acquired (B-and T-cell) immunity.
Discussion
Th1 response is dominated by antigen-specific T lymphocytes that produce IFN-g and are cytotoxic to cells infected with intracellular pathogens such as M. tuberculosis. Hence, a Th1 response is probably required for 10, 18, 19 In contrast, a Th2 response is abundant during infection with M. tuberculosis, and thus a shift in the balance toward a Th1 response may be beneficial. 20, 21 DNA vaccination can achieve such a shift particularly because of its own 'adjuvant' effect. 22 In our previous studies, the combined DNA vaccine encoding antigens 85B, MPT64 and MPT83 stimulated a strong Th1 response, induced strong anti-mycobacterial immunity in mice and offered significant prophylactic protection. 23, 24 Moreover, combined vaccination with a tripleantigen DNA vaccine is more effective than vaccination with a single-antigen DNA vaccine. 19 Our recent results show that chemotherapy combined with immunotherapy including the combined DNA vaccine is more effective in the prevention of TB reactivation compared with chemotherapy alone, and suggest the potential of the combined DNA vaccine as a therapeutic agent. In addition, we predict that our regimen of concurrent chemotherapy and the combined DNA vaccine would be clinically more useful than a regimen involving sequential DNA vaccination and chemotherapy. 12, 25 Many attempts have been made to elucidate the nature of the TB antigens involved in stimulating protective IFN-g production, which is dramatically reduced in patients with active TB in response to challenge with M. tuberculosis antigens Ag85A, Ag85B, MTB41 and ESAT-6, suggesting that these are candidate protective antigens. 19, 26 Mouse immunization experiments have shown that vaccination with DNA encoding Ag85B generates strong CD4 + T-cell-mediated Th1 and CD8 + T-cellmediated cytotoxic T-lymphocyte responses, and is responsible for improved protection against challenge by virulent M. tuberculosis in animal models. MPT-64 is recognized by sera prepared from human TB patients and is capable of eliciting a cytotoxic T-cell response. MPT83 is also a sero-dominant antigen in M. bovis and is well recognized by T lymphocytes from infected animals.
In the present study, we demonstrate for the first time that the combined DNA vaccine along with INH+PZA is effective at reducing the proportion of mice carrying detectable residual infection (Table 1) . Furthermore, the proportions were found to inversely correlate with IFN-g production in response to the three specific antigens. These results suggest that Ag85B, MPT-64 and MPT-83 could act as protective antigens in a therapeutic mode. Notably, the combined DNA vaccine along with INH+PZA significantly enhanced the production and concentration of IFN-g by 3-to 4-fold compared with mice that were given chemotherapy alone (Figure 2a) . Thus, the DNA vaccine encoding the three antigens might either boost antigen-specific T cells generated during chemotherapy or produce new antigen-specific T cells. These T cells would generate an efficient Th1 immune response, including IFN-g production, and eventually inhibit the growth of M. tuberculosis.
Although conventional chemotherapy has shown high cure rates in TB patients, it requires long-term therapy of more than 6 months. Immunotherapy, using the combined DNA vaccine, along with chemotherapy for more than 3 months showed a stronger therapeutic effect compared with chemotherapy alone; in the lungs of these mice, bacterial counts were 15-to 30-fold lesser than counts in mice treated with only INH+PZA at 12-20 weeks after treatment (Table 2) . Thus, we suggest the possibility that immunotherapy, using the combined DNA vaccine, along with INH+PZA might shorten the period of conventional chemotherapy.
Obviously, M. tuberculosis infection alters the host's immune status. Therapeutic effect is associated not only with initiating a Th1 response but also with switching the insufficient Th2 immune status to the more protective Th1 response. Higher IL-12 production in our work ) determined by sandwich ELISA.
c NO production was evaluated by the method of Griess. *Po0.01 and **Po0.001 indicate statistically significant differences for adhesion, activation and signaling markers of pulmonary macrophages from vaccine-and INH+PZA-treated mice in relation to INH+PZA-treated mice (Tukey's ANOVA). These data are from a typical experiment (n=5) repeated three times with similar results.
Efficient TB therapy with INH+PZA and combined DNA vaccine D-H Yu et al polarized the Th1-type immune responses and magnified and extended the IFN-g and IL-2 responses, because IFN-g production is partially regulated by IL-12 (Table 3) . In this regard, Seder 27 reported that persistent IL-12 exposure (via an IL-12 DNA vaccine construct) was essential for the maintenance of a persistent cellmediated response against another intracellular parasite. NO is an important mediator in the control of M. tuberculosis infection. 28 Higher NO levels detected in splenocytes of mice treated with combined DNA vaccine and antibiotics may therefore enhance resistance of mouse to M. tuberculosis infection.
In summary, the present study demonstrates that vaccination with Ag85B, MPT-64 and MPT-83 DNA during chemotherapy conferred a protective effect against M. tuberculosis reactivation. We speculate, therefore, that this vaccine regimen-when used prophylactically and therapeutically-might be able to both prevent the establishment of a latent state and eliminate M. tuberculosis that is already established.
Materials and methods

Animals and bacterial strains
M. tuberculosis strain H37Rv was obtained from the Beijing TB Therapeutic Tumor Institute. Escherichia coli DH5a and TOP10 strains were maintained in our laboratory, grown on LB medium and used for cloning preparations. For expression of histidine-tagged antigens, an E. coli BL21 (DE3)/pLysS strain (Invitrogen, Carlsbad, CA, USA) was transformed with pET22b-based expression vectors. Specific pathogen-free C57BL/ 6 female mice were obtained from the Animal Center at the Academy of Military Medical Sciences (Beijing, China). The mice, maintained in a BL-3 biohazard animal room in barrier conditions at the Beijing TB Therapeutic Tumor Institute, were 6-8 weeks old at the time of infection and were fed with commercial mouse chow and water.
DNA vaccine and recombinant protein preparations
The pJW4303 vector, kindly provided to us by Professor J Mullins of Stanford University, was used for all DNA vaccine constructs in this study. The coding regions for antigens Ag85B, MPT64 and MPT83 were amplified from M. tuberculosis H37Rv chromosomal DNA using specific primers designed according to the corresponding genome sequence obtained from GenBank. The primers for Ag85B, MPT64 and MPT83 have been described. 29 All antigen-coding regions were separately fused to the tissue plasminogen activator (TPA) signal sequence. We verified all DNA constructs by commercial DNA sequencing (Invitrogen). The parental vector, pJW4303, was used as the negative control. DNA for immunization was purified using the Qiagen EndoFree Mega Plasmid DNA kit (Qiagen, Valencia, CA, USA) and was diluted in saline solution to final concentrations of 1-2 mg ml
À1
. Recombinant proteins were prepared as described previously. 29 
DNA vaccination therapy for established infection
Briefly, starting 8 weeks after intravenous infection with 5 Â 10 5 live M. tuberculosis H37Rv organisms, mice were treated with INH at 25 mg kg À1 day À1 and PZA at 1000 mg kg À1 day À1 in the diet for 12 weeks. Bacterial counts were taken from the lungs and spleens of mice at 12 and 20 weeks after the completion of the 12-week course of chemotherapy to confirm the clearance of cultivable organisms (Figure 1 ).
Immunotherapy with DNA vaccines
During the course of the chronic infection model experiment described above, the whole preparation of the combined DNA vaccine (1.5 mg ml
À1
; 200 ml per mouse) was divided into two equal portions and 150 mg in 100 ml was injected intramuscularly into the tibialis anterior muscle of each hind leg. Control mice were immunized with 300 mg of the parental vector, pJW4303 DNA. Mice were immunized three times at intervals of 4 weeks. During the course of INH+PZA treatment, viable bacteria in tissues from mice were counted at 12 and 20 weeks after the completion of treatment, as described above.
Evaluation of cytokine production in vitro
Spleens from five mice in each group were removed aseptically at 32 weeks post-infection. The spleen cells were adjusted to a concentration of 4 Â 10 6 cells ml
À1
before being cultured in round-bottomed microwell plates (Nunc, Roskilde, Denmark) in RPMI-1640 medium supplemented with L-glutamine, 2-mercaptoethanol (50 mM), penicillin (100 U ml À1 ), streptomycin (100 mg ml
) and heat-inactivated fetal calf serum (final concentration, 10%; Gibco-BRL, Gaithersburg, MD, USA). From each tube (five samples per group), 180 ml of cell suspension was added to 20 ml of the purified recombinant antigens separately (final protein concentration 5 mg ml
) or PPD (20 ml of 10 mg ml
). Cells were incubated at 37 1C in a humidified CO 2 incubator and supernatants were harvested after 72 h. Supernatants from three separate wells were pooled and frozen at À80 1C. The concentrations of cytokines IFN-g, IL-4 and IL-12 in the supernatants were measured by ELISA using paired cytokine-specific monoclonal antibodies according to the manufacturer's instructions (BD PharMingen, San Diego, CA, USA).
IFN-g ELISPOT assay
To assess IFN-g secretion, a multiscreen 96-well filtration plate (polyvinylidene difluoride membranes; Millipore, Billerica, MA, USA) was coated with 10 ml ml À1 antimouse IFN-g-capture antibody (BD PharMingen) and incubated overnight at 4 1C. Plates were blocked and washed as per the manufacturer's instructions. Spleen cells from all groups were plated in triplicate at 1 Â 10 5 cells per well in 100 ml medium and then stimulated with the mixture of specific antigens (final concentration 2.5 mg ml À1 for each antigen) for 48 h at 37 1C. PPD (10 mg ml
À1
) was also used to stimulate the cells acquired from each group. The cells were removed and plates were subsequently washed and incubated overnight at 4 1C with a biotin-conjugated anti-mouse IFN-g secondary antibody (BD PharMingen). The filters were developed with prepared streptavidin-horseradish peroxidase solution at 100 ml per well and incubated for 1 h at room temperature. Spots were visualized and counted using the Champ Spot II ELISPOT reader system (Sage Creation, Beijing, China). 
Analyses of lymphocyte subpopulations
To investigate the activation of T cells, mouse CD4 (L3T4) or CD8 (Lyt-2) antibody-conjugated Dynabeads (Dynal Biotech ASA, Oslo, Norway) were added directly to the spleen cell suspension obtained according to the manufacturer's specifications. The cell/bead mixture was then placed on a magnet for 1 min to collect the rosetted cells on the wall of the conical tube. The efficacy of cell depletion was greater than 98%, as determined by flow cytometry (data not shown). After incubating at 37 1C for 48 h in 5% CO 2 with or without (control) mixed antigens (5 mg ml À1 for each antigen) or PPD (10 mg ml À1 ), lymphocytes were incubated with specific antibodies against different surface markers. The antibodies used were anti-mouse monoclonal antibodies CD44-PE and CD62L-FITC (Serotec, Oxford, England). Then the samples were analyzed with a FACScan calibrator (BD Corporation, San Jose, CA, USA). Ten thousand cells were analyzed per sample. Five mice from each group and three samples from each animal were used for statistical analysis.
Determination of NO production
The procedure for NO determination was based on the Griess reaction. Culture supernatant (100 ml) or sodium nitrite standard (0-200 mM) was mixed with an equal volume of Griess reagent (Sigma-Aldrich, St Louis, MO, USA). Culture supernatants were acquired as described above in 'Evaluation of cytokine production in vitro'. In addition, anaerobic conditions were achieved by purging the reaction with high-purity argon gas for at least 5 min. After 5 min at room temperature, the absorbance at 550 nm (A 550 ) was measured.
Histopathology
For histopathological examination, organs were collected at different time points, fixed in 10% buffered formalin and paraffin-embedded. From the paraffin-embedded tissue blocks, 2-3 mm sections were prepared and stained with hematoxylin and eosin. The tissues were coded and evaluated by a board-certified pathologist having no knowledge of the treatment groups.
Statistical analysis
The statistical analysis of bacterial counts, cytokine levels and all survival data was performed by one-way ANOVA using the SigmaStat 3.5 program (Systat Software Inc., Richmond, CA, USA).
